FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely nephrology and may be used for treating polycystic kidney disease. That is ensured by administering an effective amount of 40-O-(2-hydroxyethyl)rapamycin, and also the inhibitor inosine-5'-monophosphate dehydrogenase additionally.
EFFECT: using the given inventions allows for the higher clinical effectiveness in polycystic kidney disease.
6 cl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING TUBEROUS SCLEROSIS | 2007 |
|
RU2473343C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| TREATING FIBROTIC DISEASES | 2007 |
|
RU2491934C2 |
| COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR | 2009 |
|
RU2538683C2 |
| TREATING NEUROENDOCRINE TUMOURS | 2006 |
|
RU2487711C2 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| STENTS WITH COATING CONTAINING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYL-AMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINAMIN | 2003 |
|
RU2341266C2 |
| CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
